Upcoming System Maintenance

Notice:Promega will be performing essential system updates January 21–25.

Order processing and shipping will pause starting January 21 at 4:00 PM CST and resume on January 26.
Please plan to order in advance for any products needed during this timeframe.

Please contact Customer Service with any questions.
Phone: (608) 274-4330
Toll-Free Phone: (800) 356-9526
Email: custserv@promega.com
Hours: 8am-5pm CST, Monday-Friday

Improved DAMP Assays for the In Vitro Assessment of Immunogenic Cell Death

Part # PS405

Abstract

Andrew L. Niles, Kevin R. Kupcho, Dan F. Lazar and James J. Cali
Promega Corporation

The extracellular levels of damage-associated molecular patterns (DAMPs) released during immunogenic cell death (ICD) are positively correlated with the magnitude and efficacy of the resulting in vivo immune response. Therefore, extracellular ATP (eATP) and high mobility group box 1 (HMGB1) have been identified as key biomarkers for their predictive capacity during in vitro ICD screening activities. Current methods for identifying eATP and HMGB1 inducers are laborious and costly and are hampered by poor throughput. 

To overcome these challenges, we have developed easy-to-use, homogeneous, bioluminescent assays that measure dose-dependent release of these immunostimulatory agents directly in cell culture. The RealTime-Glo™ Extracellular ATP Assay measures eATP, and the Lumit™ HMGB1 Immunoassay measures HMGB1 release. 

Together, the assays represent an efficient means of evaluating the ICD inducing potential of new chemical entities or other treatment modalities.